AD, The most common inflammatory skin disorder worldwide, is a highly heterogeneous condition with current treatments that do ...

Winter depression can take a toll on your mind and body. Local health experts say depression is something you should take ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...

The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

Johnson & Johnson (NYSE ... point happened after the late 2021 approval for the treatment of bipolar depression. Caplyta is on track to generate nearly $700 million in net sales in 2024 and ...

Johnson & Johnson will pay Intra-Cellular shareholders ... which treats schizophrenia and bipolar I and II depression. The company also has other drugs in the pipeline to treat Alzheimer's Disease ...

Johnson & Johnson (J&J ... Its shares rose following a recent settlement with Sandoz over Caplyta, a bipolar depression medication. Meanwhile, J&J's market capitalisation reportedly stands ...

Johnson & Johnson on Monday said it has agreed to acquire ... a medicine known as Caplyta that’s approved in the U.S. to treat schizophrenia and bipolar depression. The biotech recently asked the Food ...